The working theory is that GLP-1s protect the heart through a combination of better metabolic control, lower inflammation, and direct vascular and cardiac benefits
Nausea and vomiting Diarrhea Constipation Stomach pain Indigestion and burping Decreased appetite Fatigue Dizziness Faster heart rate Injection site reactions Hair loss Overall, about 56% of people taking tirzepatide for weight management reported at least one digestive side effect, compared with 30% of people taking a placebo
Were a LegitScript-certified telehealth provider that connects you with licensed U.S
Unlike a class action lawsuit, people with a lawsuit in an MDL have an individual case
But the question I have is when you were giving this to the diabetics, which was the precedent, that was really what these drugs were first intended, they didn't lose that much weight, and they never, still today when it's looked at for obese non-diabetics versus diabetics, there's a gap in weight loss
-Glutamyl transpeptidase is increased by oxidative stress in rat alveolar L2 epithelial cells
